Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941648 | 0.93 | DRD2 (0.34) | DRD2DRD4CHEK2MCHR1SLC6A3 | |
| SCHEMBL4750542 | 0.90 | MCHR1 (0.37) | DRD2DRD4CHEK2MCHR1ACHE | |
| SCHEMBL14582408 | 0.86 | NPC1 (0.43) | DRD2DRD4CHEK2MCHR1SLC6A3 | |
| SCHEMBL4750205 | 0.85 | SLC6A3 (0.38) | MCHR1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4947343 | 0.85 | MCHR1 (0.36) | DRD2DRD4CHEK2MCHR1SLC6A3 | |
| SCHEMBL14582409 | 0.84 | DRD2 (0.35) | DRD2DRD4CHEK2SLC6A3SLC6A2 | |
| SCHEMBL4749039 | 0.82 | MAOB (0.42) | SLC6A3SLC6A4ACHE | |
| SCHEMBL4751555 | 0.81 | CHEK2 (0.38) | DRD2DRD4CHEK2SLC6A3SLC6A2 | |
| SCHEMBL4949797 | 0.80 | ACHE (0.38) | SLC6A3SLC6A4ACHE | |
| SCHEMBL4950186 | 0.78 | NPC1 (0.43) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | DRD2 51/4885DRD4 129/4885CHEK2 4073/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | DRD2 51/4885DRD4 129/4885CHEK2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.